# BCG Against Covid-19 for Prevention and Amelioration of Severity Trial (BAC to the PAST)

> **NCT04534803** · PHASE3 · WITHDRAWN · sponsor: **Harvard Medical School (HMS and HSDM)**

## Conditions studied

- Covid19

## Interventions

- **DRUG:** BCG Vaccine
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04534803
- **Lead sponsor:** Harvard Medical School (HMS and HSDM)
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-09
- **Primary completion:** 2022-05
- **Final completion:** 2022-07
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** At this time it has been decided by the study team the the study will no longer take place in the United States.
- **Last updated:** 2021-06-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04534803

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04534803, "BCG Against Covid-19 for Prevention and Amelioration of Severity Trial (BAC to the PAST)". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT04534803. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*